Small molecule · developed by Enanta Pharmaceuticals
EDP-305 is a drug studied in nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04378010 | Phase 2 | Non-Alcoholic Steatohepatitis | Terminated | ENTA |
| NCT03421431 | Phase 2 | Non-Alcoholic Steatohepatitis | Completed | ENTA |
| NCT03394924 | Phase 2 | Primary Biliary Cholangitis | Completed | ENTA |
| NCT03783897 | Phase 1 | NASH - Nonalcoholic Steatohepatitis | Completed | ENTA |
| NCT03207425 | Phase 1 | NASH | Completed | ENTA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
NASHNASH - Nonalcoholic SteatohepatitisNon-Alcoholic SteatohepatitisPrimary Biliary Cholangitis
Updated Oct 11, 2026. Something wrong or missing? Report it on the ENTA page.
See ENTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ENTA catalysts and pipeline →